Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

Recent & Breaking News (TSXV:VM)

Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes

TheNewsWire 15 hours ago

Voyageur Receives $600K Grant from Alberta Innovates for Product Development

TheNewsWire 13 days ago

Voyageur Secures $687k of Additional Capital from Warrant Exercises

TheNewsWire January 23, 2025

Voyageur Pharmaceuticals is going global: Why it's time to buy the stock

Trevor Abes  January 23, 2025

Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite

TheNewsWire January 15, 2025

Voyageur Commences Testing of Innovative Barium Contrast Product Line in Human Radiology Scans, Paving the Way for Near-Term Market Launch

TheNewsWire January 13, 2025

Canadian Investment Regulatory Organization Trade Resumption - VM

Canada NewsWire December 20, 2024

Voyageur Pharmaceuticals Ltd. Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio

TheNewsWire December 20, 2024

Voyageur Announces Closing of Final Tranche of Private Placement

TheNewsWire December 18, 2024

Voyageur Announces Closing of First Tranche of Private Placement

TheNewsWire December 3, 2024

Voyageur Announces Extension to Complete Proposed Private Placement

TheNewsWire November 26, 2024

Voyageur Pharmaceuticals announces $1M raise for contrast drug testing

Coreena Robertson October 29, 2024

Voyageur Announces Proposed Private Placement

Newsfile October 17, 2024

One of the best Venture pharma stocks has grown even stronger

Jonathon Brown October 3, 2024

Voyageur Pharmaceuticals Grants Stock Options

Newsfile September 25, 2024

Voyageur Pharmaceuticals Strengthens Leadership Team with Strategic Appointment of Dr. Ibrahim Hashmi as VP of Business Development

TheNewsWire September 24, 2024

Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company's Research and Innovation Leadership

TheNewsWire September 17, 2024

Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry

TheNewsWire September 5, 2024

Voyageur Pharmaceuticals Grants Deferred Share Units

TheNewsWire July 9, 2024

Revolutionizing medical imaging with nanocarbon-based contrast drugs

Jocelyn Aspa June 13, 2024